NCT02521649View on ClinicalTrials.gov

Dose-ranging Study to Evaluate Antibody Response to G17DT in Patients With Gastric Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

September 30, 1998

Primary Completion Date

January 31, 2001

Study Completion Date

January 31, 2001

Conditions
Gastric Cancer
Interventions
DRUG

G17DT

Sponsors
All Listed Sponsors
collaborator

Clinical Project Services

UNKNOWN

collaborator

MPS Research Unit

UNKNOWN

lead

Cancer Advances Inc.

INDUSTRY